Home
This site is intended for healthcare professionals

Key Clinical Summary: AUD Practice in Action

AUD: Practice in Action — Key Clinical Summary

This is a key clinical summary of the "AUD: Practice in Action" satellite symposium session at World Congress of Psychiatry on Sept 25th 2026. Revisit the session and see disclosures here.

This session was supported by an independent medical education grant from Lilly.

Introduction

The symposium explored alcohol use disorder (AUD) through a longitudinal patient case, connecting three clinical decisions: identification and diagnosis, treatment planning and goal alignment, and coordinated care with ongoing evidence integration. The central message was that identifying AUD is only the beginning: patients need a pathway that connects diagnosis with treatment initiation, engagement and sustained follow-up.

1. Identification and Diagnosis: Look Beyond the Presenting Complaint

Include alcohol assessment in the psychiatric work-up. AUD may first become apparent when a patient presents with depression, anxiety, poor sleep or an incomplete response to psychiatric treatment. Assessment should include alcohol and other substance use, medication adherence, suicide risk, possible mania or hypomania, and medical contributors. Preserved employment or apparently maintained daily functioning should not prevent further assessment.

Ask systematically and without stigma. Explain why alcohol is relevant to the patient’s symptoms and treatment. Use validated questions and neutral, person-first language rather than assumptions about who is likely to have AUD. Describing symptoms and their consequences can be more useful than asking patients to accept a diagnostic label at the outset.

Distinguish screening from diagnosis and severity. The Alcohol Use Disorders Identification Test–Consumption (AUDIT-C) is a brief screen for unhealthy or risky alcohol use; it does not establish an AUD diagnosis or determine diagnostic severity. A positive result should lead to a structured symptom assessment. Under DSM-5-TR, AUD involves a problematic pattern of alcohol use causing clinically significant impairment or distress, with at least two qualifying symptoms occurring within a 12-month period. Severity is classified as mild with 2–3 criteria, moderate with 4–5, and severe with 6 or more.

The teaching case illustrated this distinction. Elena’s AUDIT-C score of 7 prompted further assessment; five identified DSM-5-TR criteria supported a diagnosis of moderate AUD: drinking more than intended, unsuccessful attempts to cut down, craving, reduced activities and continued use despite recurrent interpersonal problems. Withdrawal and tolerance were not reported. Their absence did not exclude AUD.

Assess psychiatric symptoms concurrently. Establish the temporal relationship between mood symptoms and alcohol use rather than assuming that one fully explains the other. In Elena’s case, the available history did not establish whether her depressive symptoms were independent, alcohol-related or both. This uncertainty should prompt continued assessment without postponing appropriate AUD care.

2. Treatment Planning and Goal Alignment: Agree a Meaningful, Measurable First Step

Start with the patient’s priorities and clinical risks. Elena wanted better sleep and fewer relationship difficulties but was uncertain about stopping alcohol completely. The session emphasised collaborative goal-setting: explore what the patient wants to change, explain the available treatment approaches and agree a measurable next step. Goals should be revisited rather than treated as fixed decisions.

Individualise reduction and abstinence goals. The treatment-goal framework on slide 27 presented reduction or abstinence as potential goals, depending on AUD severity, patient preference and clinical factors. Abstinence remains particularly important in higher-risk circumstances, including pregnancy and advanced liver disease. An initial reduction goal should involve active treatment and planned reassessment, not indefinite continuation of harmful drinking without review.

Consider medication and behavioural support as complementary options. For many patients, evidence-based care involves pharmacological treatment alongside behavioural or psychological support, tailored to an agreed goal. These approaches should not automatically be delivered sequentially, with one withheld until the other has failed. Uncertainty about committing to abstinence should not become a universal barrier to beginning appropriate care.

The pharmacotherapy discussion included naltrexone, nalmefene, acamprosate and disulfiram. Selection requires consideration of the treatment goal, current alcohol use, comorbidities, contraindications, patient preferences and locally applicable guidance. Relevant checks include current or anticipated opioid use, hepatic or renal function as appropriate to the medicine, adherence, and the need for supervision or support.

For Elena, the proposed approach was to discuss pharmacotherapy appropriate to her reduction goal, arrange behavioural support and establish early follow-up, while remaining open to a future abstinence goal.

3. Coordinated Care and Evidence Integration: Make the Plan Actionable

Define responsibilities across the care team. Integrated care requires more than several services being involved. The pathway should specify who manages AUD and psychiatric symptoms, monitors physical health, provides behavioural treatment, supports engagement and adjusts or escalates care. Psychiatry, addiction specialists, primary care, behavioural therapists and peer or community services may contribute according to the patient’s needs and available services.

Make referrals explicit and maintain continuity. A referral should communicate the diagnosis and severity, agreed treatment goal, treatment already started, relevant psychiatric and medical risks, and follow-up arrangements. Identify who is responsible for the next action rather than assuming that responsibility has transferred because a referral has been sent. Delayed referrals, missing information, unscheduled follow-up and unclear care ownership were highlighted as potential points of disengagement.

Monitor more than alcohol consumption. Follow-up should assess drinking and heavy-drinking days, craving, mood, sleep, daily functioning, adherence, adverse effects and safety. Review whether the patient is moving towards the agreed goal and whether treatment needs to continue, change or intensify. Monitoring only becomes coordinated care when a named clinician or team reviews the findings and acts on them.

Escalation triggers. The session distinguished three responses:

  • Urgent reassessment: suicidality, major psychiatric deterioration, severe withdrawal risk or acute medical instability.
  • Intensified or better-coordinated care: drinking that is not reducing, worsening depression, poor adherence or tolerability, or repeated missed follow-up.
  • Continuation with review: measurable progress towards the goal, stable mood and functioning, and treatment that is tolerated and maintained.

Escalation should respond to defined clinical signals rather than waiting for treatment to fail completely.

Connect evidence to specific clinical decisions. Validated assessment informs diagnosis; pharmacological and behavioural guidance informs treatment; response and safety findings inform monitoring; and updated evidence can inform treatment adjustment or escalation. The practical task is to identify which decision or workflow step should change, then adapt the pathway accordingly.

Conclusion

The symposium emphasised a connected approach to AUD care: ask systematically, establish the diagnosis and severity, agree an individualised treatment goal, initiate appropriate evidence-based care, and assign responsibility for follow-up. A positive screen, a treatment discussion or a referral is not a complete pathway. The plan must remain active as the patient’s response, circumstances and available evidence evolve.

Clinical application: Medication availability, authorised indications and monitoring requirements vary by country. Apply locally applicable clinical guidance and current prescribing information. This summary is an educational resource, not a prescribing protocol.